Polycystic Ovary Syndrome: Detailed Examination and Management Strategies

The document from 2018 provides a detailed examination of Polycystic Ovary Syndrome (PCOS), a disorder affecting 5%-20% of women of reproductive age, characterized by symptoms such as hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. It explains that PCOS is diagnosed using the Rotterdam 2003 criteria, which require at least two of the following features: chronic anovulation, polycystic ovaries, and hyperandrogenism. The document highlights the complex genetic nature of PCOS, with a heritability of around 70% and 16 loci identified through GWAS. It discusses the distinct pathophysiology of insulin resistance in PCOS, which differs from that in Type 2 Diabetes Mellitus or obesity, and the associated clinical manifestations, including dermatologic issues like hirsutism, acne, and androgenic alopecia, as well as menstrual irregularities and increased risks of various health complications. Management strategies for PCOS include lifestyle changes, medical therapies targeting insulin resistance, hyperandrogenism, and fertility issues, with specific treatments such as metformin, thiazolidinediones, inositol isomers, statins, OCPs, antiandrogens, and fertility treatments like clomiphene citrate and IVF. The document also emphasizes the importance of individualized treatment approaches and the impact of PCOS on quality of life, suggesting the use of the PCOSQ questionnaire for assessment.